Free Newsletter
Study: Statins don't cause cancer
We know statins lower LDL, or "bad" cholesterol. We also know that they tend to lower HDL, or "good" cholesterol, too. And we suspect that it's possible for low LDL levels to boost the risk of cancer. So, do statins increase the risk of cancer? Well, no, according to a new metanalysis published in the Journal of the American College of Cardiology.
The study found that yes, statins lowered LDL and that patients with lower LDL did have a greater risk of cancer. But, their statistics showed, the statins weren't the culprit in that cancer risk. You see, the people in the studies who didn't take statins also had a higher risk of cancer if their LDL was lower. And that risk in both lower-LDL groups was roughly the same.
Still, cardiology experts said that the FDA and drugmakers should analyze their statin trial data for cancer incidence, because the possible link between very low LDL and cancer is worrisome--and therefore it might not be safe to use statins to push cholesterol to super-low levels. That could trade lower cardio risk for higher cancer risk.
--read the item at Pharmalot
--see the study in JACC
--check out an analysis from Heartwire
Related Articles:
Cholesterol drug market shifts
Heresy: Do we need cholesterol meds?
Pathway found to raise "good" cholesterol
Statins could be linked to Parkinson's disease
Study: Statins offer non-surgical cardio therapy
Switching to generic statins not so healthy
Comments
Hello Tracy, you've mixed up your characterization of LDL as good cholesterol and HDL as bad cholesterol - it's the other way around. Corinne Foo-Atkins
Please note that HDL is the "good" cholesterol and LDL in the "bad" cholesterol. Your first sentence is incorrect. Get it right.
You have your good and bad lipid fractions mixed up: HDL is so-called "good" cholesterol which you want to increase, and LDL is "bad" which you want to decrease with weight loss, diet or drugs.
Thank you all for your comments. The mistake has been noted and corrected.
Thank you,
FiercePharma
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: